Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities
- PMID: 15661408
- DOI: 10.1016/j.eururo.2004.09.007
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities
Abstract
Objectives: This review aims to provide practising clinicians with the most recent knowledge of the biological nature of prostate cancer (PC) to facilitate investigation of new treatment modalities for patients with PC, especially the hormone-refractory state of the disease.
Methods: Review of the literature using PubMed search and scientific journal publications.
Results: Much progress has been made towards an understanding of the development and progression of PC, and the factors which drive the development of androgen independence. Neuroendocrine (NE) cells may provide an intriguing link between NE cell differentiation and tumour progression in PC with the genetically supported formation of androgen-independent clones which regulate the proliferation of neighbouring non-NE-phenotype cancer cells in a paracrine manner by secretion of NE products. Various NE peptides stimulate proliferation of androgen-independent PC through transactivation of the androgen receptors (AR). Therefore, cancerous epithelial cells that increase their responsiveness to NE factors or induce NE cells to release trophic factors may have a survival advantage over their siblings.
Conclusion: This review shows the need to improve our understanding of the biological nature of PC, especially cancer cells of the NE phenotype and their regulatory products to develop new therapeutic protocols and trials based on NE hormones and their agonists/antagonists.
Similar articles
-
Neuroendocrine differentiation in prostate cancer: from lab to bedside.Urol Int. 2007;79(4):287-96. doi: 10.1159/000109711. Urol Int. 2007. PMID: 18025844 Review.
-
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.Cancer Res. 2000 Feb 1;60(3):741-8. Cancer Res. 2000. PMID: 10676662
-
Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.G Chir. 2010 Nov-Dec;31(11-12):568-74. G Chir. 2010. PMID: 21232206
-
The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.J Endocrinol Invest. 2005;28(11 Suppl International):141-5. J Endocrinol Invest. 2005. PMID: 16625864 Review.
-
Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.Oncogene. 2008 Jan 17;27(4):506-18. doi: 10.1038/sj.onc.1210656. Epub 2007 Jul 16. Oncogene. 2008. PMID: 17637748
Cited by
-
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047. J Pathol. 2012. PMID: 22553170 Free PMC article.
-
Small-cell neuroendocrine cancer of the prostate: an atypical presentation of a common disease.BMJ Case Rep. 2016 Oct 5;2016:bcr2016216199. doi: 10.1136/bcr-2016-216199. BMJ Case Rep. 2016. PMID: 27707760 Free PMC article.
-
Recent advances in tissue stem cells.Sci China Life Sci. 2021 Dec;64(12):1998-2029. doi: 10.1007/s11427-021-2007-8. Epub 2021 Nov 30. Sci China Life Sci. 2021. PMID: 34865207 Review.
-
The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.PLoS One. 2018 Jul 12;13(7):e0200472. doi: 10.1371/journal.pone.0200472. eCollection 2018. PLoS One. 2018. PMID: 30001402 Free PMC article.
-
Molecular pathways and targets in prostate cancer.Oncotarget. 2014 Sep 15;5(17):7217-59. doi: 10.18632/oncotarget.2406. Oncotarget. 2014. PMID: 25277175 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials